IPCS INCHEM Home

    HYDROGENATED GLUCOSE SYRUPS (HGS)

    EXPLANATION

         Hydrogenated glucose syrups (HGS) are a mixture of polymers of
    glucose obtained from starch by hydrolysis which, upon hydrogenation,
    results in chemical reduction of the end-group glucose molecule to
    sorbitol. HGS consists primarily of maltitol and sorbitol, with lower
    portions of hydrogenated oligo- and polysaccharides.

         Hydrogenated glucose syrups were evaluated for acceptable daily
    intake by the Committee at its twenty-fourth and twenty-seventh
    meetings (Annex 1, references 53 & 62). At the twenty-seventh meeting,
    the Committee decided, on the basis of acute and subacute tests and
    reproduction and metabolism studies, to allocate a temporary ADI of
    0-25 mg/kg b.w. to hydrogenated glucose syrups containing 50-90%
    maltitol. The Committee at that time requested that the results of a
    lifetime feeding study should be made available.

    BIOLOGICAL DATA

    Biochemical aspects

    Absorption, distribution, biotransformation, and excretion

         In male Swiss mice given single oral doses of either 14C-
    maltitol or 14C-glucose, expired 14CO2, faecal 14C, and blood 14C-
    concentrations were determined from 5 to 240 minutes post-
    administration. Labelled 14C from maltitol was absorbed into the
    blood from the gastrointestinal tract much more slowly, exhaled
    substantially less, and excreted via the faeces significantly more
    than 14C from glucose. Glucose and sorbitol, but not maltitol, were
    detected in the blood of treated animals (Kamoi, 1975).

         Five to 10 male or female Sprague-Dawley rats/group were given
    single oral doses, by gastric intubation, of 200, 400, or 600 mg
    sorbitol, maltitol, or HGS (containing 6-8% sorbitol, 50-55% maltitol,
    20-25% hydrogenated tri- to hexasaccharide, and 15-20% hydrogenated
    polysaccharide of more than 6 units) and were killed 1.5, 3, or 7
    hours post-administration. Only a small quantity of non-hydrolysed
    maltitol crossed the intestinal barrier, since its concentration in
    blood was very small. Urinary excretion of sorbitol, maltitol, or HGS
    accounted for about 1% of the ingested quantity over a 7-hour period.
    Administration of increasing doses of maltitol or HGS resulted in
    increased concentrations of sorbitol and decreased concentrations of
    maltitol in the gastrointestinal tract, which demonstrates that the
    alpha-l,4 glucose-sorbitol linkage of maltitol is hydrolysed and
    liberates glucose and sorbitol (Verwaerde & Dupas, 1982a).

         Two series of 10 male Sprague-Dawley rats (5 treated and 5
    control rats) were housed individually in metabolic cages. The treated
    rats drank a solution of HGS (18% W/V) for 10 days, and thereafter
    pure water until sacrifice. The control animals received water only.
    One series of rats was sacrificed on day 11; the other series was
    sacrificed on day 21. Sorbitol and maltitol were determined daily in
    urine and plasma, and the liver, kidneys, and spleen were removed from
    the animals at terminal sacrifice. After maltitol ingestion per day
    ranging from 2.97-4.27 g in males, the maximum quantity of maltitol
    excreted per day was 6.27 ± 4.50 mg (the maximum excretion coefficient
    was 0.14%); in females, the amount ingested ranged from 2.46-3.03
    g/day, and the maximum quantity of maltitol excreted per day was 2.04
    ± 1.2 mg (the maximum excretion coefficient was 0.09%). The ingestion
    of HGS resulted in very small quantities of maltitol in the urine.
    Twenty-four hours following the removal of HGS from the rats, the
    quantity of maltitol excreted in the urine was reduced to essentially
    nil. Maltitol was absent in the plasma, liver, kidneys, and spleen of
    treated animals. In addition, the ingestion of HGS did not affect the
    sorbitol content in the examined organs (Verwaerde & Dupas, 1982b).

         Groups of 35 male Wistar rats (about 200 g each) received by
    gavage 1.2 ml of a 50%-aqueous solution of maltitol, xylitol,
    sorbitol, or glucose, and their blood glucose and residual sugar
    alcohols in the digestive tract were determined hourly for 6
    consecutive hours. Animals given the sugar alcohols exhibited lower
    blood glucose values than animals receiving glucose itself. Maltitol
    disappeared from the digestive tract the most quickly of the sugars
    that were investigated (Takae et al., 1972).

         Weanling Wistar rats placed on diets containing 13 or 26%
    maltitol for 9 weeks had reduced body-weight gains and increased
    intestinal weights as compared with controls. Enzymatic tests in dosed
    rats indicated that the alpha-glycosidic linkage of maltitol was not
    hydrolysed with pancreatic enzymes or enzymes of the intestinal
    mucosa. Maltitol dehydrogenase was not observed in liver-cell
    cytoplasm and prolonged maltitol administration did not induce hepatic
    sorbitol dehydrogenase (Inoue, 1970).

         Maltitol was administered to rats either by gastric probe at a
    dosage of 2 g/kg or i.v. at a dosage of 1 g/kg. Blood glucose and
    insulin levels and the liver glycogen content were measured at
    4.5 hours. Maltitol induced hyperglycemia similar to that observed by
    the administration of an equivalent amount of glucose or sucrose
    (Lederer et al., 1974).

         Ten grams maltitol was given to fasted germ-free or normal rats
    by stomach tube. Urine and faeces were collected for 24 hours after
    intubation and analysed for sorbitol and maltitol. No glucose was
    detected in the urine or faeces of any of the animals, and there was
    no significant difference in the maltitol content of the urine. The

    sorbitol content of the urine was higher in germ-free than in normal
    animals, but no statistical differences were found. In normal animals
    there was a 96% utilization of maltitol, while in germ-free animals,
    utilization was 84%, indicating that microbial utilization is not the
    major factor in maltitol metabolism. Maltitol injected i.v.
    (0.25 g/animal) was excreted almost quantitatively (88%) in the urine,
    producing no significant rise in blood glucose. No sorbitol was
    detected in the blood. The small amount of sorbitol in the urine
    indicated slight utilization of maltitol in body tissues (Kearsley
    et al., 1982).

         Intestinal perfusions were carried out with 6 rats (WAG/Rij),
    5 females and 1 male, monoassociated with aerobic bacilli that are
    unable to metabolize maltitol. A solution (0.18 ml/min) containing
    85 mM maltitol and 0.1% (w/v) polyethylene glycol 4000 was infused in
    the duodenum. Maltitol and polyethylene glycol were estimated in the
    lower ileum during a period of 4 hours. The portion of maltitol
    absorbed over the distance of the whole small intestine was found to
    be 19 ± 4%. Therefore, under the experimental conditions used,
    2.9 µmol maltitol/min, was hydrolysed (the ingested amount was
    15.3 µmol/min) (Zunft et al., 1983).

         By stomach tube 5 ml of an aqueous solution of 30% (w/v,
    4.36 mmole) maltitol and 1% (w/v) polyethylene glycol were introduced
    into the stomachs of 8 gnotobiotic rats. For comparison, the same
    amount of maltose was administered to 3 rats. The animals were killed
    by decapitation 60-120 min. after application. Maltitol, maltose, and
    polyethylene glycol were found only above the ileocaecal valve. The
    maltitol:polyethylene glycol quotient decreased in going from the
    stomach to the small intestine. Only 31% of the ingested maltitol was
    found in the ileum after 2 hours (Zunft et al., 1983).

         Rats (groups of 3 or 6) were given a single oral dose of 1 or 2 g
    maltitol. Very little of either maltitol or sorbitol appeared in the
    faeces, but appreciable amounts of sorbitol found in the urine
    indicate that the maltitol had been hydrolised. When HGS was
    administered, the pattern of excretion was similar, but the quantities
    of both maltitol and sorbitol in the urine were significantly higher
    (Lian-Loh et al., 1982).

         Excretion of maltitol and sorbitol were compared in germ-free and
    normal rats given oral doses of 2 g maltitol. Significantly less of
    both substances was recovered in the faeces of normal rats, but
    urinary excretion was similar in both groups. Three rats were injected
    with maltitol (250 mg/animal). The dose was virtually cleared from the
    blood within 1 hour, and at most the equivalent of approximately 30 mg
    was recovered as sorbitol in the excreta after 24 hours. There was no
    evidence of a rise in blood glucose after injection of maltitol.
    Little or no metabolism of maltitol had occurred in the tissues
    because hydrolysis was catalyzed by gastric or intestinal enzymes
    (Lian-Loh et al., 1982).

         Wistar rats were dosed orally with a 20%-maltitol solution
    (320 mg/kg, containing about 1.28 µCi maltitol-U-14C per 100 g b.w.).
    A second group was dosed with maltitol-U-14C and fasted 24 hours.
    Urine, faeces, and 14CO2 were collected. The rate of 14CO2
    excretion in respired air of the fed group was more rapid than that of
    the fasted group; of the CO2 excreted within 24 hours (18.0%), 90%
    was excreted within 8 hours after dosing. The 14CO2 excretion per
    unit time was high in the fed group between 2 and 4 hours after
    dosing. The fasted group showed a high excretion rate between 2 and 6
    hours after dosing, and the decline thereafter was more moderate than
    that observed with the fed group. About 22% of the dosed maltitol was
    hydrolysed in the fed group, while that of the fasted group was about
    33%. Excretion in the urine of 14C-derivatives was more rapid in the
    fasted group than in the fed group. About 50% of the 14C excreted in
    the urine was maltitol, while the figure for the fed group was about
    34%. The results show that a portion of the administered maltitol was
    not metabolized, but was absorbed in the intestinal tract and quickly
    excreted in the urine (Oku et al., 1981).

         Five Charles-River rats (both sexes represented) were dosed with
    radioactive maltitol solution by intubation (125-260 mg/kg, 49.7 µCi).
    After dosing, 1 animal was placed in a breath collection chamber; the
    other 4 were placed in individual metabolism cages. Exhaled carbon
    dioxide was collected over a period of 14 hours. Urine and faeces were
    collected either over a period of 48 hours (2 rats) or 72 hours
    (3 rats). The rapid (1-2 hours) and appreciable appearance of 14CO2
    (45.5% in 14 hours) in the breath indicates that a portion of the
    maltitol was hydrolised in the stomach and the resulting components,
    glucose and sorbitol, were absorbed and catabolically utilized. The
    calculated caloric utilization was 76%. Radioactivity in the urine
    varied from 3.94 to 9.40% in 72 hours. The faeces contained
    4.38-13.22% of the ingested radioactivity at 72 hours. Thirteen
    percent of the total faecal radioactivity was due to volatile fatty
    acids (Rennhard & Bianchine, 1975).

         HGS or maltitol (400 mg) was administered by gastric intubation
    to groups of 10 male rats (5 fasted and 5 fed). Rats were sacrificed
    after 7 hours. The tested products and their metabolites were then
    examined in the digestive tract and in the urine. The results showed
    that the alpha-1,4 glucose-sorbitol linkage was hydrolysed in rats,
    whether fasted or not. Seven hours after the administration of either
    HGS or maltitol, small quantities of free maltitol were detected in
    the digestive tract of fasted and fed rats (2.5 (fasted) and 3.8 mg
    after HGS administration, 6.2 (fasted) and 4 mg after maltitol
    administration). Sorbitol liberated by digestive hydrolysis of
    maltitol or HGS was more rapidly absorbed by fed rats than by fasted
    rats. However, this does not seem to affect maltitol or sorbitol
    urinary excretion (Verwaerde & Dupas, 1984).

         Two male beagle dogs were given maltitol-U-14C (51.2 µCi) by
    stomach tube. Blood samples were collected until 32 hours after

    dosing. The peak radiolabel concentration in plasma was 2 hours after
    maltitol administration (304 and 263 µg/ml, expressed as maltitol
    equivalent in the 2 dogs). The radioactivity present in the urine
    after 48 hours was 7.8 and 3.8% of the administered dose in the
    2 animals (Rennhard & Bianchine, 1975).

         In vitro investigations on maltitol utilization by human
    intestinal flora indicate that some strains of Lactobacillae,
    Enterobacteriaceae klebsiella, Bacteroidaceae, and
    Catanabacterium utilize maltitol (Mitsuoka, 1982a; 1982b).

         In an in vitro study of 14C-U-maltitol in everted intestinal
    sacs, the highest transport of 14C-maltitol was displayed in the
    jejunum, followed by the ileum and duodenum. Twenty-four hours after
    oral administration of 14C-U-maltitol, 60% of the radioactivity was
    detected in the caecum, large intestine, and faeces. Five percent was
    excreted in the urine and 1.2% was expired as CO2 within 24 hours.
    When 14C-U-maltitol was injected i.v., over 35, 60, and 85% of the
    administered dose was excreted in the urine within 1, 3, and 24,
    hours, respectively (Oku et al., 1971).

         In vitro digestion of HGS and its main components was
    investigated using enzymes from human and rat intestinal mucosa for
    periods of 0.5 to 24 hours. The amount of maltitol present in HGS
    governed the enzymatic hydrolysis of its components. Maltitol was
    hydrolysed slowly by the intestinal mucosa of man (3.56%) and rat (7%)
    when compared with maltose, of which 76% and 26%, respectively, was
    hydrolysed (Verwaerde, 1982).

         High disaccharidase activity for sucrose, maltose, and maltitol
    was found in the jejunum of female Wistar rats. Less was observed in
    the ileum and duodenum. Disaccharidase activity for maltitol was
    extremely low compared with that for sucrose and maltose. Kinetic data
    indicate that both maltose and maltitol compete for the same
    intestinal disaccharidase (Yoshizawa et al., 1975).

         Pieces of New Zealand rabbit small intestine were everted and
    incubated with 100 mM substrate (maltitol, sucrose, or glucose). After
    removal at different times (20, 40, or 60 min.) of incubation, the
    volume of serosal fluid and the dry mass of the gut pieces were
    determined. Maltitol was hydrolysed, and the hydrolysis products were
    absorbed by the everted sacs. No maltitol was detected in the serosal
    fluid. The serosal glucose concentration increased at a slower rate
    after incubation with maltitol than after incubation with glucose or
    sucrose. The rate of hydrolysis and absorption decreased with the
    longer time of incubation (Zunft et al., 1983).

         An enzymatic maltase/glucoamylase system isolated from the
    intestinal mucosa of the rat was used in an hydrolysis study. After
    40 hours of incubation with different substrates, the percentage of
    hydrolysis was 100% for maltose, 91% for maltitol, and 79-95% for HGS.

    The maltase/glucoamylase system hydrolysed maltose more quickly than
    maltitol (200 and 15 nmoles/minute, respectively) (Montreuil et al.,
    1983).

    Toxicological studies

    Special studies on mutagenicity

         HGS was evaluated in a series of assays for assessing the
    mutagenic potential of chemicals.

         HGS did not induce a significant increase in genetic mutations in
    the Schizosaccharomyces pombe strain in a host-mediated assay
    (mouse) at doses up to 1 g/kg (Mondino et al., 1979a).

         HGS was not mutagenic against 4 strains of Salmonella
    typhimurium at concentrations of 0.01 to 1 ml/plate (0.2-20 mg),
    with or without activation by rat liver microsomes (Fouillet et al.,
    1978a; 1978b; Hofnung, 1978).

         Eight male Sprague-Dawley rats (4 controls) received daily by
    gavage doses of HGS equivalent to 0, 2.5, 5, 10, 15, or 20% in the
    diet for 15 consecutive days. Urine from each rat was collected on day
    15. Urine that had been concentrated and purified was assayed for
    mutagenic activity against Salmonella typhimurium strains TA98,
    TA100, TA1535, TA1537, and TA1538 using the Ames test with or without
    metabolic activation. No mutagenic effects were found (Farrow, 1983d).

         A micronucleus test was conducted in which HGS was administered
    orally to adult male mice at doses of 10 or 50 ml/kg on 2 consecutive
    days. The animals were killed 6 hours after the second administration
    of HGS. Femoral bone marrow was taken, and 2000 polychromatic
    erythrocytes per animal were counted and scored for micronuclei. The
    administration of HGS did not significantly increase the mean
    percentage of polychromatic erythrocytes carrying micronuclei (Siou
    et al., 1981).

         HGS at concentrations of 0.5 to 1000 µg/plate was not mutagenic
    in the Ames test with Salmonella typhimurium strains TA98, TA100,
    TA1535, TA1537, or TA1538 with and without metabolic activation
    (Mondino et al., 1979b).

         HGS did not induce a significant increase in the incorporation of
    3H-thymidine into human heteroploid fibroblasts at concentrations up
    to 300 µg/ml (Mondino, 1980).

         HGS was added in vitro to C3H/10T 1/2 (Clone 8) mouse
    fibroblast cells using concentrations from 10 to 1000 µg/ml with or
    without metabolic activation. There was a significant increase in the
    prevalence of morphologically transformed foci due to exposure to HGS
    (Farrow & Sernau, 1982; Farrow, 1982c).

         The potential of HGS to induce forward mutations at the thymidine
    kinase locus in the L5178Y mouse lymphoma cell line was assessed at
    concentrations ranging from 27 to 1000 µg/ml in the presence or
    absence of metabolic activation. HGS induced a slight increase in
    mutation frequency, but the increase was not dose-related (Farrow,
    1982b).

         The ability of HGS to induce mutations in Chinese hamster ovary
    cells in vitro was investigated at concentrations ranging from 49 to
    4900 µg/ml. No significant increase in the frequency of structural
    chromosomal aberrations was seen at any of the concentrations tested,
    either with or without metabolic activation (Farrow, 1982a).

    Special study on reproduction

    Rats

         A multigeneration reproduction study in Sprague-Dawley rats was
    conducted, in which males received 5.4-8.5 g HGS per day and females
    received 5.3-13.5 g of the same compound per day in drinking water as
    an 18% (dry weight/volume) aqueous solution for 3 successive
    generations, each comprising 2 consecutive litters. Concurrent
    controls were given water only. The initial number of animals in each
    generation was 10 males and 10 females.

         During the study, food consumption was lower for treated animals
    than for controls, but without irreversible effect on the growth rate
    except for females of the F2 generation. Animals from most groups may
    not have had decreased growth rates due to the caloric compensation of
    HGS in the drinking water. No abnormal behaviour was detected during
    treatment.

         Among the organ weights recorded, the kidneys of treated rats had
    lower weights and caeca had higher weights than concurrent controls.
    Haematology and gross pathology of parents were not remarkable.
    Fertility, length of gestation, litter size, number of live and
    stillborn pups, post-natal survival, and the lactation index were not
    affected by treatment. Sex ratios of treated litters exhibited an
    approximate 10% decrease in the number of female pups (Leroy & Dupas,
    1983).

    Special study on teratogenicity

    Rats

         HGS was administered by gavage to groups of 30 pregnant Sprague-
    Dawley rats from day 6 to day 15 of gestation, inclusive, at dosage
    levels of 0, 3000, 5000, or 7000 mg/kg/day. A control group received
    the vehicle, distilled water, at the same dosage volume through the
    same period. On day 20 of gestation, all rats were killed and the
    number of corpora lutea in each ovary and the number, position, and 

    condition of implantations were recorded. Viable foetuses were
    weighed, sexed, and examined externally. The thoracic and abdominal
    cavities of the remainder were dissected, examined, and then processed
    for subsequent skeletal examination. No adverse effects were observed
    on pregnant females or on litter responses (litter size, foetal
    weight, or pre- and post-implantation losses). No visceral or skeletal
    abnormalities in the foetuses attributable to the treatment were
    observed (Dupas & Siou, 1985).

    Acute toxicity
                                                                     

                                  LD50
      Species        Route        (mg/kg b.w.)      Reference
                                                                     

    Mouse, male      oral         24,370            Dupas, 1982a
      & female

    Mouse            oral         16,000            Yamasaki et al.,
                                                    1973a

    Mouse, male      i.p.         10,640            Dupas, 1982a

    Mouse, female    i.p.         12,430            Dupas, 1982a

    Mouse            i.p.         18,500            Yamasaki et al.,
                                                    1973b

    Mouse, male      i.v.         6,390             Dupas, 1982a

    Mouse, female    i.v.         8,150             Dupas, 1982a

    Mouse            i.v.         12,000            Yamasaki et al.,
                                                    1973b

    Mouse            s.c.         24,000            Yamasaki et al.,
                                                    1973b

    Rat, male &      oral         24,370            Dupas, 1982b
      female

    Rat, male &      oral         24,000            Nishibori, 1968
      female

    Rat              oral         24,130            Kotani & Chiba,
                                                    1968

    Rat, male &      i.p.         13,000            Dupas, 1982b
      female
                                                                     

    Short-term studies

    Rats

         Groups of 20 Sprague-Dawley rats, evenly divided by sex, were fed
    diets containing 1, 15, or 20% HGS for 3 consecutive months. The diet
    of the controls was supplemented with 20% sucrose. No effects on
    mortality, growth, or food consumption were observed. No diarrhoea or
    other clinical symptoms were noted. No treatment-related effects were
    reported after ophthalmological examination, and organ weights were
    normal. Slight decreases in haemoglobin levels and erythrocyte counts
    occurred in both sexes of the 15%- and 20%-groups at week 4 and week
    13 of treatment. Blood urea concentrations increased slightly in all
    treated females at week 4. Moderate elevation of blood urea and
    glucose were noted in all treated rats at week 13. Slight elevation of
    blood phosphous occurred in both sexes fed 15 and 20% of the test
    material at week 13 of the test. Gross and histopathological changes
    observed were not remarkable (Coquet et al., 1980).

         Forty weanling Sprague-Dawley rats, equally divided by sex,
    were fed 20% HGS for 90 consecutive days. The same number of controls
    were fed a diet supplemented with 20% sorbitol. No mortality or
    noteworthy clinical symptoms occurred. No effects on haematology,
    blood chemistry, urinalysis, or organ weights were noted. Gross and
    microscopic examination revealed no histopathological alterations in
    organs or tissues at termination (Stevens et al., 1980).

    Dogs

         Four male or 4 female beagle dogs received 4.95 g/kg HGS every
    day for 13 weeks. Clinical examinations were performed daily and all
    animals were autopsied. Food intake in the treated animals was
    slightly decreased throughout the study, without any effect on the
    animals' body-weight gain. Ophthalmologic examinations did not reveal
    any abnormalities caused by the treatment. The only significant
    effects that were observed involved the occurrence of diarrhoea.
    Haematological and urinary analyses did not reveal any abnormalities
    linked with treatment. At autopsy, no lesions signifying an effect of
    treatment were observed. Organ weights were not modified (Virat,
    1982).

    Long-term studies

    Rats

         Weanling Wistar-derived male rats were divided into groups of 10
    each and fed 0, 5, 10, 20, or 30% of either maltitol or sucrose, or
    20% HGS, for 31 weeks. Body weights were reduced at week 4 in groups

    of 20 and 30% maltitol and 20% HGS, but were similar between the
    treated and control groups at week 8. At termination, body weights and
    selected organ weights of groups fed 5 to 30% maltitol were similar to
    rats fed 5 to 30% sucrose (Wada, 1972).

         Groups of 15 male or 15 female young Wistar rats were fed diets
    containing 0, 1, 3, or 10% HGS for up to 13 months. Mortality, food
    and water consumption, body weights, haematology, blood chemistry,
    urinalysis, and organ weights were similar between the treated and
    control rats. At the 6-month interim sacrifice, about half of the
    treated rats exhibited dilation of the stomach. Slight edema of the
    colonic mucosa in half of the treated rats was observed at month 3 and
    in about 10% of the treated rats at month 6. At termination, the
    histopathological changes were comparable between the dosed and
    control animals (Yamasaki et al., 1973c).

         Three groups of 26 male or 26 female Wistar rats were fed diets
    containing 0, 3, or 10% HGS for 78 weeks. An interim sacrifice of
    3 males and 4 females per group was carried out at week 52. After week
    50, mortality increased in both groups of dosed males, but only in the
    high-dose female group. Males of the high-dose group weighed
    substantially less than controls after week 60. Haematology, blood
    chemistry, and organ weights at interim and terminal sacrifices were
    similar between the dosed and control rats. The incidence of
    non-neoplastic lesions was not remarkable. Increased incidences of
    neoplasms of adrenal glands occurred in the dosed females and of the
    thyroid gland in the dosed males. Tumours of the skin and mammary
    region were not compound-related. Neoplasms of internal organs and
    tissues other than the above endrocine glands were not observed
    (Shimpo, 1977).

         HGS was administered in drinking water to groups of 100 Sprague-
    Dawley rats (50 males and 50 females) at concentrations of 0 or 18%
    (w/v) for 24 months. The HGS consumption measured during the study
    was: 13.9 g/kg/day and 21.5 g/kg/day for males and females,
    respectively.

         Weight gains in both groups were essentially identical, except
    for during a short preliminary period of adaptation. Subsequently, the
    treated female body weights were nearly always slightly higher than of
    the control females. The treated male body weights, which were
    slightly lower during the first year, increased during the second year
    to slightly exceed those of the control group.

         Diarrhoea, which appeared from the first week of the study, and
    which decreased from the fourth week in treated animals, is usual in
    animals receiving drinking water with high osmotic properties.

         Adaptation to the diet was also the cause of considerable caecum
    hypertrophy.

         Haematological and clinical chemical parameters did not reveal
    changes related to the test material. The only significant variation
    observed in treated males and females as compared with the control
    groups was a decrease in urea levels due to considerably higher water
    consumption by treated rats.

         Urinalysis did not show treatment-related differences.

         Histopathological examination did not show any tissue changes
    related to HGS ingestion.

         The spontaneous mortality rate recorded during the study was
    lower for treated males than for control males (5 vs. 13,
    respectively). Among females, mortality was slightly higher in the
    treated group than in the control group (11 vs. 8, respectively).

         Neoplasms of internal organs and tissues occurred with the same
    frequency in control and treated animals (Dupas et al., 1984).

    Observations in man

         Six fasted normal volunteers (3 men and 3 women) and 4 diabetics
    (1 man and 3 women) were given orally 30 g of maltitol or 30 g of
    sucrose, and at 0.5-, 1-, 1.5-, 2-, and 3-hour periods post-
    administration the glucose and maltitol concentrations in blood and
    urine were analysed. Maltitol administration induced lower blood
    glucose levels than the sucrose administration, both in normal and
    diabetic volunteers. Urinary excretion of maltitol was also low
    (Atsuji et al., 1982).

         Three normal volunteers, 3 diabetics, and 1 subject infected with
    acute hepatitis, were administered orally 50 g of glucose, sorbitol,
    or maltitol in aqueous solution, and at 0-, 0.5-, 1-, 2-, and 3-hour
    intervals post-administration the blood concentrations of these sugars
    were measured. Maltitol concentrations peaked at 0.5 hour and
    decreased sharply thereafter. Glucose followed a similar pattern, but
    its concentration was significantly higher than maltitol, especially
    in diabetics (Nishikawa, 1982).

         Twenty-seven children, 3 to 14 years of age, consumed 18 to 42 g
    of hard candies made either from sucrose or HGS within one hour. At
    this dosage, the children developed slight nausea and "hate to eat
    more" symptoms, whether the candies were made from sucrose or from
    HGS. Only 3 children, from both groups, developed mild flatulence
    (Leroy, 1982b).

         Twenty, 30, 40, or 60 g HGS or sucrose were consumed in bolus
    form by groups of 6-10 volunteers in a double-blind study. Ingestion
    of a single dose of 60 g HGS resulted in 80% of the volunteers
    reporting either abdominal discomfort, watery diarrhoea, colic, or an

    increase in flatus production. At lower doses, incidences of these
    symptoms were marginal. In another experiment, 10 different volunteers
    consumed intermittently 30, 60, or 120 g HGS or 64 g sucrose daily for
    2 days in divided doses. The highest dose produced abdominal symptoms
    in 50% of the subjects, whereas at the lowest dose, symptoms occurred
    in about 20% of the volunteers. In yet another experiment, groups of
    10 volunteers took either 30 g HGS or 30 g sucrose daily for 21 days,
    while groups of 12 subjects consumed 15 g HGS, 15 g sorbitol, or 15 g
    sucrose daily for 28 days. In all subjects taking HGS for 21-28 days,
    no adverse symptomology other than mild flatulence in 5 subjects at
    the higher dose was observed. Haematological and biochemical indices
    (liver function, glucose, cholesterol, lipoproteins, plasma insulin,
    and triglycerides) were not remarkable (Abraham et al., 1981).

         Nine diabetics (5 men and 4 women) each received a single oral
    dose of 50 g maltitol, 50 g glucose, or 7 consecutive daily doses of
    50 g each of sucrose, powdered starch syrup, or maltitol. At 0, 1, 2,
    and 3 hours post-administration the blood levels of glucose, immuno-
    reactive insulin (IRI), free fatty acids (FFA), and triglycerides (TG)
    were determined. Single doses of maltitol produced lower blood glucose
    and IRI levels but higher FFA and TG concentrations than glucose
    administration itself. The presentation of results from the multiple
    administration are unclear for the purpose of evaluation (Takeuchi &
    Yamashita, 1972).

         In a similar study, blood glucose and IRI concentrations
    exhibited flatter curves when 10 normal volunteers and 5 diabetics
    received a single oral dose of 50 g HGS than when 50 g glucose was
    administered (Yamakubi, 1971).

         In a preference test on the sweetening power and quality of
    sweetness of HGS compared with sucrose, 20 young women preferred
    sucrose over HGS for its sweetening power, but both sugars scored
    identically in terms of the quality of sweetness (Yamakubi, 1971).

         Eleven diabetics (6 men and 5 women) and 9 healthy control
    volunteers (7 men and 2 women) were given single oral doses of 50 g
    maltose or 50 g maltitol. Lower increases in blood glucose and
    IRI were observed with maltitol administration than with the
    administration of maltose. An additional 10 diabetics and 10 healthy
    control volunteers were offered "Zenzai", a thick bean syrup sweetened
    either with maltitol or with sucrose. Lower increases in blood glucose
    levels were observed in subjects that consumed "Zenzai" sweetened with
    maltitol than with sucrose. In the preference test, no significant
    differences were recorded in the intensity and quality of sweetness of
    "Zenai" sweetened with either substance. No unfavourable side effects
    were observed (Mimura et al., 1972).

         The influence on carbohydrate metabolism of HGS (containing 89%
    maltitol) has been studied in healthy humans by measuring blood
    glucose and insulin levels after various oral dosages of HGS. Subjects
    given oral doses of glucose were used as controls. Six volunteers were
    given on different occasions 50 g of glucose or HGS at dosages of 10,
    25, or 50 g. Blood glucose levels after the administration of maltitol
    were much less than after the administration of glucose; the area
    under the blood glucose curve after the administration of 50 g HGS
    represented about 25% of the area under the curve after glucose
    administration. Similarly, insulin levels were significantly lower
    after HGS ingestion than after glucose ingestion. At a dose of 10 g
    HGS, practically no increase in blood glucose or insulin was observed
    (Secchi et al., 1982).

         Groups of 16 to 36 volunteers per dose level ingested daily 12 to
    60 g of maltitol for 3 consecutive days. Ingestion of 50 or 60 g of
    maltitol induced diarrhoea in 15 and 30% of the volunteers,
    respectively (Nikken Chemicals, 1982).

         Chemical changes in the blood induced by maltitol were compared
    with those induced by glucose in both healthy people and patients with
    several disorders, including diabetes mellitus. Blood glucose levels
    of healthy subjects were determined after the administration of
    glucose (12.5, 25, or 50 g) or maltitol (50 g). Based on the glucose
    absorption curve, 38% of the maltitol that was orally administered was
    absorbed through the intestinal tract, but the absorption of maltitol
    was more delayed than that of glucose.

         After administration of maltitol to the groups with diabetes and
    the other diseases with impaired glucose tolerance, blood glucose
    levels were higher than in healthy people. Elevation of blood glucose
    levels by maltitol was 25 to 50% of the elevation by glucose, and
    there was a correlation between the elevation of blood glucose by
    glucose and by maltitol.

         The peak blood glucose level after administration of a mixture of
    50 g glucose and 50 g maltitol was lower than after the administration
    of 50 g glucose alone. Diarrhoea was frequently observed in healthy
    people and in patients with a borderline glucose tolerance test
    pattern after oral administration of maltitol. However, the frequency
    of diarrhoea was very low in patients with diabetes or the other
    disease with impaired glucose tolerance patterns (Kamoi et al.,
    1975).

         Ten men and 7 women volunteers consumed daily 20 hard candies
    containing about 80 g/day of sweet product, for 2 consecutive weeks in
    a blind trial. Each volunteer was offered for 1 week sucrose control
    candies and for the other week the candies made from HGS. A majority

    of volunteers complained during both trial weeks of digestive
    disorders, such as loss of appetite, occasional diarrhoea, cramps, and
    a "bloated feeling". At the dosage level of 80 g/day of hard candies
    made from HGS, the limit of tolerance was exceeded (Leroy, 1982a).

         Five normal men, 23 to 56 years old, ingested in the early
    morning on an empty stomach 0.5 g/kg/day maltitol for 30 consecutive
    days. On days 1, 7, and 30 at 1, 2, and 3 hours after the daily
    administration of maltitol, the concentrations of maltitol and glucose
    in the blood were measured and serum levels of protein, cholesterol,
    bilirubin, uric acid, urea nitrogen, SGOT, SGPT, LDH, sodium,
    potassium, and calcium were determined. Diarrhoea was not observed. In
    3 volunteers, blood glucose levels increased by about 20% 1 hour after
    maltitol administration. No other changes were observed (Itoya et
    al., 1974).

         One hundred seven men (including 11 diabetics) and 20 women
    (including 2 diabetics) were offered daily 30 to 180 ml of a 50% HGS
    solution in 2 equal daily doses for periods up to 4 months. They were
    examined daily and subjected to extensive monthly blood chemistry
    analyses. Occasional diarrhoea or accelerated intestinal transit
    occurred at higher doses, more frequently in women than in men. Both
    sexes tolerated 30 ml/day for up to 4 months without any clinical or
    digestive manifestations (Tacquet & Devulder, 1978).

         Fifteen subjects received single oral doses of 50 g glucose or
    40-50, 80, or 100 g HGS. At 0-, 0.5-, 1-, 1.5-, 2-, 2.5-, and 3-hour
    intervals post-administration, the blood concentrations of glucose and
    insulin were determined. Maltitol excretion was measured in urine 3
    hours after administration. Blood glucose and insulin peaked at 0.5
    hour after administration of either glucose or HGS, but the increases
    after administration of HGS were less than after glucose
    administration. The data on maltitol excretion in urine were not
    conclusive (Debry, 1983).

         Five healthy women and 5 diabetics (3 males and 2 females) were
    offered single oral doses of either 50 g glucose or 50 g HGS on 2
    different occasions. Another group of 5 normal volunteers (1 male and
    4 females) and 5 diabetics (3 males and 2 females) were given orally
    25 g sucrose, 25 g sorbitol, or 33 g HGS on 3 different occasions. At
    0-, 0.5-, 1-, 1.5-, 2-, and 3-hour periods post-administration, the
    concentrations of serum glucose and insulin were determined.
    Administration of glucose produced the highest serum glucose
    concentrations. Insulin levels in normal volunteers given HGS varied
    between insulin levels in those volunteers administered sucrose and
    sorbitol. Among diabetics, there were virtually no differences
    observed after the administration of the different sugars (Vessby,
    1982).

         Thirty-five subjects (10 females and 25 males) were divided into
    3 groups and given 50, 85, or 125 g/day HGS. Subjects were required to
    ingest each solution in 6 equal doses, 1 every 2.5 hours, and were
    asked to record any intestinal discomfort, flatulence or diarrhoea. Of
    the 12 subjects that consumed 50 g/day, 2 had diarrhoea, flatulence,
    and abdominal pain. At 85 g/day, 3/12 subjects had diarrhoea,
    flatulence, and abdominal pain. At 125 g/day, 6/11 subjects had
    diarrhoea, flatulence, and abdominal pain.

         No differences were noted between male and female subjects. The
    authors concluded that over 85 g HGS could be tolerated without undue
    problems to most subjects if taken over a period of one day.
    Intestinal discomfort, flatulence, and diarrhoea increased in severity
    with intake of HGS (Kearsley et al., 1982).

         Sixteen subjects (8 females and 8 males) who had fasted overnight
    received 0.5 g/kg of one of 5 different substances (HGS, maltitol,
    glucose, glucose and sorbitol in the ratios found in HGS, or high-
    maltitol syrup). No glucose was detected in the urine of any of the
    subjects after ingestion of any of the test carbohydrates. There were
    no significant differences in polyol levels in the urine among
    subjects administered HGS, the glucose/sorbitol mixture, or high-
    maltitol syrup. Blood glucose and serum insulin profiles indicated no
    differences among subjects administered HGS, maltitol, and the
    glucose/sorbitol mixture. All these substances induced lower peak
    values for glucose and insulin than did glucose. The results indicate
    that HGS and high-maltitol syrup are metabolized to approximately the
    same extent as their basic components (Kearsley et al., 1982).

         Six male subjects were placed on a strictly-controlled diet
    containing 40% carbohydrate and 60% protein for 10 days. No lipids
    were included except when part of a protein source. Total daily
    caloric intake was about 1800 calories. The carbohydrate in the diet
    consisted of HGS, high-maltitol syrup, 43% glucose syrup, or glucose
    (the standard). Total sample intake was about 160 g/day, in 6 equal
    doses. The results of blood glucose and serum insulin analyses
    indicate that prolonged consumption of high-maltitol syrup or HGS
    leads to some adaption to these compounds as judged by elevated blood
    glucose and insulin peak values at the end of the trial. Diarrhoea and
    flatulence gradually disappeared after 4-5 days of consuming these
    hydrogenated samples. No problems were encountered with either glucose
    or 43% glucose syrup, and urine and faeces analysis revealed no
    carbohydrate present after ingestion of these samples. Subjects
    ingesting HGS or high-maltitol syrup excreted up to 10 g sorbitol and
    0.5 g maltitol in the urine and up to 8 g sorbitol and 11 g maltitol
    in the faeces over the trial period. Over 99% of the hydrogenated test
    materials were retained in the body and were therefore presumably
    utilized. This was substantiated by the steady body weights exhibited
    by all subjects throughout the trial (Kearsley et al., 1982).

         Two healthy volunteers (aged 30 and 35 years) each received a
    test meal of 69.5 g maltitol on an empty stomach. Twenty minutes after
    oral administration, blood glucose concentrations had increased by 20
    and 30 mg/dl, respectively. They remained at this level for 2 hours
    and started to normalize 3 hours after maltitol application. At that
    time, the 2 individuals suffered from diarrhoea (2 and 3.5 hours,
    respectively) (Zunft et al., 1983).

         Daily amounts of 35 g maltitol were given with meals for a period
    of 10 days to 4 subjects aged 34-53 years. Subjective signs
    (flatulence, gripes, and nausea) and faecal parameters (amount,
    frequency, pH, and content of maltitol) were compared with data from a
    control period without maltitol application. During the 10-day test
    period, there were no significant alterations of frequency and amount
    of faeces or of the pH. No maltitol was detected in the excreta by
    thin-layer chromatography (Zunft et al., 1983).

         Four healthy men (21-23 years of age) were given daily doses of
    10 g maltitol containing 79.65 µCi 14C-U-maltitol for a period of 7
    days. Expired breath, blood, urine, and faeces were collected. An
    average of 17% of the total 14CO2 recovered was exhaled within the
    first 2 hours, and 43% of the total 14CO2 was exhaled within 4
    hours. The total recovery of 14CO2 suggests a caloric utilization of
    maltitol in man of approximately 90%. This value is substantiated by
    the low radioactivity levels found in the faeces (5%) and by the
    presence of appreciable quantities of radioactive metabolites in the
    blood and urine 7 days after administration (Rennhard & Bianchine,
    1975).

    Comments

         Several metabolic studies have been performed in rats and in man
    with HGS containing 50-90% maltitol. HGS is metabolized to glucose and
    sorbitol by disaccharidases in the intestinal mucosa. Data on the
    velocity of hydrolysis in comparison to the natural substrate maltose
    show that the maltitol hydrolysis rate corresponds to 5-7% that of
    maltose; maltose inhibits the hydrolysis of maltitol. Maltitol is
    absorbed in trace amounts, with a maximum of 0.05% of the ingested
    dose excreted as maltitol in human urine. Sorbitol, a hydrolysis
    product of maltitol, is absorbed very slowly. The second cleavage
    product, glucose, is produced at a slow rate due to the slow
    hydrolysis of maltitol; it is partially metabolized, like sorbitol, by
    the bacteria of the lower intestine. Sorbitol inhibits the absorption
    of glucose.

         After the administration of 14C-maltitol, 13% and 5% of the
    administered radioactivity was recovered in rat and human faeces,
    respectively; 13% of the total radioactivity found in rat faeces was
    represented by volatile fatty acids. The total urinary excretion of
    the administered radioactivity (4-5%) was comparable for rats and

    humans. A further indication that 14C-maltitol is hydrolysed in the
    stomach and that the resulting components, glucose and sorbitol, are
    absorbed and catabolically utilized, is given by the rapid (1-2 hours)
    and appreciable appearance of 14CO2 in the breath of rats. In rats,
    43% of the total 14CO2 was exhaled within 4 hours. The recovery of
    radioactivity as 14CO2 within 24 hours of administration of
    14C-maltitol was 49% and 38-59% of the administered dose for rats and
    humans, respectively.

         Studies in animals and humans revealed that HGS or its major
    component maltitol produced significantly lower blood-glucose levels
    and more stable insulin levels than glucose or sucrose due to slow
    metabolism of maltitol.

         HGS was examined in in vitro and in vivo genetic toxicity
    assays. The results from the in vitro assays, with and without
    metabolic activation, suggest that HGS does not induce a mutagenic,
    clastogenic, genotoxic, or neoplastic transformation response. No
    in vivo clastogenic effects were observed.

         Acute and short-term animal studies indicate that HGS is not
    toxic after single or repeated oral administration of large doses. In
    rats, no evidence of toxic effects of prolonged feeding of up to
    15-20% of the diet was observed. A 90-day study in dogs showed no
    evidence of adverse effects, except for diarrhoea, at a level of
    4.95 g/kg b.w./day. A multigeneration reproduction study in rats, in
    which HGS was administered in drinking water as an 18% aqueous
    solution, did not reveal any toxicologically-significant effects.
    Human tolerance studies conducted with HGS in healthy and diabetic
    subjects showed a laxative effect at intake levels of 30-50 g/day.

    EVALUATION

    Estimate of acceptable daily intake for man

         ADI "not specified". The fact that high doses of HGS exert a
    laxative effect in man, which is a common feature of polyols, should
    be taken into account when considering appropriate levels of use of
    polyols, alone and in combination.

    REFERENCES

    Abraham, R.R., Davis, M., Yudkin, J., & Williams, R. (1981).
         Controlled clinical trial of a new non-calorigenic sweetening
         agent. J. Human Nutr., 35, 165-172.

    Atsuji, H., Asano, S., & Hayashi, S. (1982). A study on the metabolism
         of maltitol, a disaccharide alcohol. Unpublished report from Keio
         University, Japan. Submitted to WHO by Anic S.p.A.

    Coquet, B., Rondot, G., & Mary, M.C. (1980). Thirteen-week oral
         toxicity study in the rat with Lycasin(R) 80/55. Unpublished
         report from Institut Franēais de Recherches et Essais
         Biologiques, l'Arbresle, France. Submitted to WHO by Roquette
         Freres.

    Debry, G. (1983). Study of glycemia and insulinemia variations after
         per os absorption of a single Lycasin(R) 80/55 dose in man.
         Unpublished report from University of Nancy, France. Submitted to
         WHO by Roquette Freres.

    Dupas, H. (1982a). Acute toxicity of Lycasin(R) 80/55: Determination
         of the LD50 in mice. Unpublished report from Roquette Freres,
         Lestrem, France. Submitted to WHO by Roquette Freres.

    Dupas, H. (1982b). Acute toxicity of Lycasin(R) 80/55: Determination
         of the LD50 in the rat. Unpublished report from Roquette Freres,
         Lestrem, France. Submitted to WHO by Roquette Freres.

    Dupas, H., Leroy, P., & D'Alayer, C. (1982). 24 months safety study of
         Lycasin(R) 80/55 on rats. Unpublished report from Roquette
         Freres, Lestrem, France. Submitted to WHO by Roquette Freres.

    Dupas, H. & Siou, G. (1985). Lycasin(R) 80/55 teratogenic
         potential study in rats. Unpublished report from Roquette Freres,
         Lestrem, France. Submitted to WHO by Roquette Freres.

    Farrow, M.G. (1982a). In vitro chromosome aberrations in
         Chinese hamster ovary cells with Lycasin(R). Unpublished report
         from Hazleton Laboratories America, Vienna, VA, USA. Submitted to
         WHO by Roquette Freres.

    Farrow, M.G. (1982b). Mouse lymphoma forward mutation assay: Lycasin
         (R). Unpublished report from Hazleton Laboratories America,
         Vienna, VA, USA. Submitted to WHO by Roquette Freres.

    Farrow, M.G. (1982c). Cell transformation assay-Lycasin(R) (Batch E
         644-B). Unpublished report from Hazleton Laboratories America,
         Vienna, VA, USA. Submitted to WHO by Roquette Freres.

    Farrow, M.G. (1982d). Body fluid analyses (rat urine): Lycasin(R).
         Unpublished report from Hazleton Laboratories America, Vienna,
         VA, USA. Submitted to WHO by Roquette Freres.

    Farrow, M.G. & Sernau, R.C. (1982). Cell transformation assay Lycasin
         (R) (Batch E-644-B) with metabolic activation. Unpublished report
         from Hazleton Laboratories America, Vienna, VA, USA. Submitted to
         WHO by Roquette Freres.

    Fouillet, X., Gutty, D., & Wolleb, U. (1978a). Report of experiments
         on the mutagen potential of Lycasin(R) 80/55 Ref. 61540 (Ames
         test). Unpublished report from Battelle Institute, Geneva,
         Switzerland. Submitted to WHO by Roquette Freres.

    Fouillet, X., Gutty, D., & Wolleb, U. (1978b). Report of experiments
         on the mutagen potential of Lycasin(R) 80/55 Ref. 62157 (Ames
         test). Unpublished report from Battelle Institute, Geneva,
         Switzerland. Submitted to WHO by Roquette Freres.

    Hofnung, M. (1978). Products examined; Lycasin(R) Syrup (80/55).
         Unpublished report from l'Institut Pasteur, Paris, France.
         Submitted to WHO by Roquette Freres.

    Itoya, N., Moriuchi, S., & Hosoya, N. (1974). Effect of oral
         administration of maltitol on human serum composition.
         J. Jap. Soc. Food Nutr., 27, 77-81.

    Inoue, Y. (1970). Effects of maltitol administration on the
         development of rats. Unpublished report from Nikken Chemicals
         Co., Omiya, Japan. Submitted to WHO by Anic S.p.A.

    Kamoi, M. (1975). Study on metabolism of maltitol. Part 1. Fundamental
         experiment. J. Jap. Diab. Soc., 18, 243-249.

    Kamoi, M., Shimizu, Y., Kawauchi, M., Fujii, Y., Kikuchi, Y.,
         Mizukawa, S., Yoshioka, H., & Kibata, M. (1975). A study on the
         metabolism of maltitol (Clinical study). J. Jap. Diab. Soc.,
         18, 451-460.

    Kearsley, M.W., Birch, G.G., & Lian-Loh, R.H.P. (1982). The
         metabolic fate of hydrogenated glucose syrups. Stärche, 34,
         279-283.

    Kotani, S., & Chiba, S. (1968). Report of acute toxicity test of
         maltitol. Unpublished report from Juntendo University, Japan.
         Submitted to WHO by Anic S.p.A.

    Lederer, J., Delville, P. & Cevecoevr, E. (1974). Study of a new sugar
         replacement: Maltitol from the Belgium sugar factory. 93,
         311-9.

    Leroy, P. (1982a). Report on the tolerance test of Lycasin(R) 80/55
         administered in the form of sweets to adult human volunteers.
         Unpublished report from Roquette Freres, Lestrem, France.
         Submitted to WHO by Roquette Freres.

    Leroy, P. (1982b). Report on the tolerance test of Lycasin(R) 80/55
         administered in the form of sweets to children. Unpublished
         report from Roquette Freres, Lestrem, France. Submitted to WHO by
         Roquette Freres.

    Leroy, P. & Dupas, H. (1983). Lycasin(R) 80/55: Three generation
         reproduction toxicity studies. Volume I - Study of reproductive
         functions. Volume II - Study of reproductive periods. Unpublished
         report from Roquette Freres, Lestrem, France. Submitted to WHO by
         Roquette Freres.

    Lian-Loy, R., Birch, G.G., & Coates, M.E. (1982). The metabolism
         of maltitol in the rat. Br. J. Nutr., 48, 477-481.

    Mimura, C., Koga, T., Oshikawa, K., Kido, K., Sadanaga, T., Jinnouchi,
         T., & Kawaguchi, K. (1972). Maltitol tests with diabetics. Jap.
         J. Nutr., 30, 145-152.

    Mitsuoka, T. (1982a). Utilization of maltitol by intestinal
         lactobacillus. Unpublished report from Institute of Physical and
         Scientific Research, Tokyo, Japan. Submitted to WHO by Anic
         S.p.A.

    Mitsuoka, T. (1982b). Utilization of maltitol by intestinal flora.
         Unpublished report from Institute of Physical and Scientific
         Research. Tokyo, Japan. Submitted to WHO by Anic S.p.A.

    Mondino, A., Fumero, S., & Berruto, B. (1979a). Study of the mutagenic
         activity in vivo of the compound Marvie(R) with
         Schizosaccharomyces pombe. Unpublished report from the
         Institute of Biomedical Research, Ivrea, Italy. Submitted to WHO
         by Anic S.p.A.

    Mondino, A., Fumero, S., Peano, S., & Berruto, P. (1979b). Study of
         the mutagenic activity of Marvie(R) compound with Salmonella
         typhimurium. Unpublished report from the Institute of
         Biomedical Research, Ivrea, Italy. Submitted to WHO by Anic
         S.p.A.

    Mondino, A. (1980). Test of DNA non-programmed synthesis stimulation
         by the product Marvie(R) in human cell (EVE) cultures.
         Unpublished report from the Institute of Biomedical Research,
         Ivrea, Italy. Submitted to WHO by Anic S.p.A.

    Montreuil, J., Bouquelet, S., Dupas, H., Verwaerde, F., & Rosiers, C.
         (1983). Study of intestinal maltase/glucoamylase in the rat.
         Unpublished report from Roquette Freres, Lestrem, France.
         Submitted to WHO by Roquette Freres.

    Nikken Chemicals (1982). Diarrhoea after Malbit(R) administration.
         Unpublished report from Nikken Chemicals Co., Tokyo, Japan.
         Submitted to WHO by Anic S.p.A.

    Nishibori, K. (1968). Study on acute toxicity test of maltitol.
         Unpublished report from Notre Dame Seishin University, Okayama,
         Japan. Submitted to WHO by Anic S.p.A.

    Nishikawa, K. (1982). Variations of blood and urine sugar values with
         oral administration of maltitol. Unpublished report from
         Nishikawa Hospital, Tadera, Japan. Submitted to WHO by Anic
         S.p.A.

    Oku, T., Inoue, Y., & Hosoya, N. (1971). Absorption and excretion of
         maltitol-U-14C in rat. J. Jap. Soc. Food Nutr., 24, 399-404.

    Oku, T., Him, S.H., & Hosoya, N. (1981). Effect of maltose and diet
         containing starch on maltitol hydrolysis in rat. J. Jap. Soc.
         Food Nutr., 34, 145-151.

    Rennhard, H.H. & Bianchine, J.R. (1975). Metabolism and caloric
         utilization of orally administered maltitol-14C in rat, dog and
         man. J. Agric. Food Chem., 24, 287-291.

    Secchi, A., Pontiroli, A.E., & Pozza, G. (1982). Influence of maltitol
         (Malbit(R)) on glycemia and insulinemia after oral
         administration. Unpublished report from Clinica Medica,
         Universitą di Milano, Italy. Submitted to WHO by Anic S.p.A.

    Shimpo, K. (1977). Long-term toxicity of "Malti" a reducing malt
         millet jelly in particular reference to tumorigenic activity in
         rats. J. Toxicol. Sci., 2, 1-28.

    Siou, G., Conan, L., & Pilatte, Y. (1981). Research of the possible
         mutagenic activity of Lycasin(R) by the micronucleus test on
         mouse. Unpublished report from Laboratoire d'Histopathologie et
         de Cytopharmacologie, Versailles, France. Submitted to WHO by
         Roquette Freres.

    Stevens, K.R., Gagliardi, J.J., & Weinberg, M.S. (1980). Comparative
         study of HSH 80/55 and sorbitol in rats when materials are
         administered in feed for 90 days. Unpublished report from Booz,
         Allen and Hamilton, Inc., Florham Park, NJ, USA. Submitted to WHO
         by Roquette Freres.

    Tacquet, A. & Devulder, A.B. (1978). Study of the clinical and
         biological tolerance of Lycasin(R) 80/55 in man. Unpublished
         report from Hōpital Calmette, Lille, France. Submitted to WHO by
         Roquette Freres.

    Takai, Y., Ito, T., & Iwao, H. (1972). A study on the variations of
         digestion and blood sugar values with the lapse of time after
         sugar administration. J. Jap. Soc. Food Nutr., 25, 162.

    Takeuchi, I. & Yamashita, M. (1972). Clinical test results of a
         disaccharide alcohol (maltitol). Eiyo to Shokuryo (Nutrition
         and Food), 25, 170.

    Verwaerde, F. (1982). Digestion in vitro by enzymes of the
    intestinal
         mucosa of rat and man of Lycasin(R) 80/55 and of its main
         fractions with a comparison with several di- and polysaccharides.
         Unpublished report from Roquette Freres, Lestrem, France.
         Submitted to WHO by Roquette Freres.

    Verwaerde, F. & Dupas, H. (1982a). Study of the in vivo digestion of
         Lycasin(R) 80/55 in the rat. Unpublished report from Roquette
         Freres, Lestrem, France. Submitted to WHO by Roquette Freres.

    Verwaerde, F. & Dupas, H. (1982b). A study of the urinary excretion
         and risks of accumulation of maltitol in certain organs of rats
         fed with Lycasin(R). Unpublished report from Roquette Freres,
         Lestrem, France. Submitted to WHO by Roquette Freres.

    Verwaerde, F. & Dupas, H. (1984). Study of the in vivo digestion of
         Lycasin(R) 80/55 in the rat. Volume III. A comparative study on
         fed and fasting rats. Unpublished report from Roquette Freres,
         Lestrem, France. Submitted to WHO by Roquette Freres.

    Vessby, B. (1982). Studies of Lycasin(R) as a sweetener in diabetes
         mellitus. Unpublished report from University of Uppsala, Sweden.
         Submitted to WHO by Roquette Freres.

    Virat, M. (1982). A 13-week toxicity study of per os administered
         product (Lycasin(R) 80/55) in dogs. Unpublished report from
         Institut Franēais de Recherches et Essais Biologiques. Submitted
         to WHO by Roquette Freres.

    Wada, F. (1972). The nutritional efficiencies of Maltit(R) (maltitol)
         and Maltit(R) syrup (hydrogenated malt - conversion starch
         syrup). Proc. 24th Jap. Food Health Assoc., Oct. 12-13.

    Yamakubi, T. (1971). Malbit(R): a new sweetener and its applications
         for diabetics Proc 14th Cong. Jap Soc. Diabetics. April 3-4.

    Yamasaki, M., Tanabe, K., & Kimishima, K. (1973a). Acute toxicity of
         Malbit(R): Examination after various means of injection.
         J. Yonago Med. Assoc., 24, 34-37.

    Yamasaki, M., Tanabe, K., & Kimishima, K. (1973b). Acute toxicity of
         Malbit(R) in mice. Investigation by various means of injection.
         J. Yonago Med. Assoc., 24, 1-10.

    Yamasaki, M., Tanabe, K., Matsumoto, Y., Tamaki, H., Kimishima, K., &
         Okamoto, S. (1973c). Toxicological studies of Malbit(R) in rats.
         J. Yonago Med. Assoc., 24, 10-30.

    Yoshizawa, S., Moriuchi, S., & Hosoya, N. (1975). The effects of
         maltitol on rat intestinal disaccharidases. J. Nutr. Sci.
         Vitaminol., 21, 31-37.

    Zunft, H.J., Schulze, J., Gärtner, H., & Grütte, F.-K. (1983).
         Digestion of maltitol in man, rat and rabbit. Ann. Nutr.
         Metab., 27, 470-476.
    


    See Also:
       Toxicological Abbreviations